Relay Therapeutics to Unveil Early Zovegalisib Data in Vascular Anomalies — Relay Therapeutics, Inc.

Event summary

Relay Therapeutics will present initial clinical and preclinical data for zovegalisib in vascular anomalies at the ISSVA World Congress 2026.
The presentation includes data from approximately 20 efficacy-evaluable patients.
Zovegalisib targets PI3Kα mutations, addressing a potential patient population of 170,000 annually in the U.S.
The drug is the first allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor developed using Relay's Dynamo® platform.

The big picture

Relay Therapeutics is positioning zovegalisib as a breakthrough in precision medicine, targeting a significant unmet need in vascular anomalies and PI3Kα-mutated cancers. The presentation at ISSVA 2026 will be a critical milestone in validating the drug's potential, especially given the challenges of developing selective PI3Kα inhibitors with minimal toxicity. The success of zovegalisib could redefine treatment paradigms for both genetic diseases and cancers driven by PI3Kα mutations.

What we're watching

Clinical Efficacy: How the initial data from 20 patients will impact the perceived potential of zovegalisib in vascular anomalies.
Regulatory Pathway: Whether the preclinical and clinical data will support accelerated regulatory approval processes.
Market Positioning: The pace at which Relay Therapeutics can differentiate zovegalisib from existing PI3Kα inhibitors in the market.